<unk>  is well absorbed after administration, reaching peak plasma levels within 1 – 2 hours. It has a very long elimination half-life and can still be detected 72 hours after dosing. Bioavailability is about 77 percent. Peak plasma levels occur at just over one hour after administration. Significant accumulation occurs of<unk>  due to its slow metabolism; the elderly metabolise<unk>  and its active metabolite slower than younger individuals, resulting in a dose of<unk>  accumulating faster and peaking at a higher plasma concentration than an equal dose administered to a younger individual. The elderly also have a poorer response to the therapeutic effects and a higher rate of adverse effects. The elimination half-life of<unk>  is 80–115 hours. The active metabolite of<unk>  is lorazepam and represents about 15 - 24 percent of the parent drug<unk> . The pharmacokinetics of<unk>  are not altered if it is taken with food, except for some slowing of absorption.<unk> s potency is approximately equal to that of lorazepam, being ten times more potent by weight than diazepam (1 mg<unk>  = 1 mg lorazepam = 5 mg diazepam), typical doses range from 0.5 mg - 2 mg. Treatment is generally initiated at 1 mg for healthy adults and 0.5 mg in pediatric and geriatric patients and patients with mild renal impairment, treatment is contraindicated in patients with moderate or severe renal impairment.
Delorazepam
Halazepam
Oxazepam
Diclazepam
Clonazepam
Medazepam
Triazolam
Gidazepam